Panacea Biotec launches tetravalent vaccine ‘Easyfour-TT’

26 Dec 2016 Evaluate

Panacea Biotec, one of India’s leading research based health management company, has launched Tetravalent Vaccine 'Easyfour-TT' for active primary immunization and booster dose against diphtheria, tetanus and pertussis (DTP) and Haemophilus Influenza Type B (Hib). Easyfour-TT (DTwP-Hib), world’s first fully liquid Tetravalent vaccine launch in India will protect infant from Diptheria, Tetanus, Whopping Cough, Hib-Meningitis.

Easyfour-TT is a sterile and uniform suspension, manufactured using CDAP technology with WHO Pre-Qualified antigens which ensures good quality, high immunogenicity and less reactogenicity. Being fully liquid, product requires no reconstitution, therefore saves time and minimizes chance of error. Easyfour-TT comes with a legacy of being a tried and tested brand in pediatric clinical trials ensuring good ethnic response with a better reactogenicity profile.

Panacea Biotec is the largest biotechnology company as well as among the top 50 pharmaceutical companies of India. The company has product portfolio that’s caters therapeutics areas like pain management, diabetes and cardiovascular management, renal disease management, osteoporosis management, anti-tubercular, gastro-intestinal.


Panacea Biotec Share Price

134.00 0.35 (0.26%)
14-Jun-2024 16:00 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1515.00
Dr. Reddys Lab 6080.25
Cipla 1565.50
Zydus Lifesciences 1110.95
Lupin 1601.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.